Form 4 for NRIX Nurix Therapeutics, Inc.
Accepted 2026-09-01 17:19:15 ET · period of report 2026-09-01 · accession 0001817160-26-000019 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-01 17:19 | 2026-09-01 | NRIX | Hansen Gwenn | CSO | M - OptEx | $1.86 | +1,452 | 118.7K | +1% | +$2,701 |
| DT | 2026-09-01 17:19 | 2026-09-01 | NRIX | Hansen Gwenn | CSO | S - Sale+OE | $25.47 | -1,452 | 117.2K | -1% | -$37.0K |
| DT | 2026-09-01 17:19 | 2026-09-01 | NRIX | Hansen Gwenn | CSO | M - OptEx | $0.00 | -1,452 | 60.9K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-01 | M | A | 1,452 | $1.86 | 118,679 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. |
| 2 | Common | Common Stock | 2026-09-01 | S | D | 1,452 | $25.47 | 117,227 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. |
| 3 | Derivative | Employee Stock Option (right to buy) | 2026-09-01 | M | D | 1,452 | $0.00 | 60,858 | D | $1.86 · — to 2029-08-28 | 1,452 Common Stock | (F1) This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. (F2) The stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019 until the option was fully vested on May 10, 2023. |